Monitoring Report: Respiratory Viruses - December 2024 Data

Samuel Gratzl*, PhD

Brianna M Goodwin Cartwright*, MS

Patricia J Rodriguez, PhD, MPH

Duy Do, PhD

Nicholas L Stucky, MD, PhD

* Denotes co-first author
Affiliations: All authors are affiliated with Truveta, Inc.

Corresponding author:
Dr Nicholas Stucky
Truveta, Inc
1745 114th Ave SE, Bellevue, WA 98004
Email: nicholass@truveta.com

Abstract

Background: Few sources regularly monitor hospitalizations associated with respiratory viruses. This study provides current hospitalization trends associated with six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus.

Objective: This study aims to supplement the surveillance data provided by the CDC by describing latest trends (through December 29, 2024) overall and for each respiratory virus. This study also provides valuable insight into two at-risk populations: infants and children (age 0-4) and older adults (age 65 and over).

Methods: Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provides more than 18% of all daily clinical care in the US, we identified people who were hospitalized between October 01, 2020 and December 29, 2024. We identified people who tested positive for any of the six respiratory viruses within 14 days of the hospitalization. We report weekly trends in the rate of hospitalizations associated with each virus per all hospitalizations for the overall population and the two high-risk sub populations: infants and children and older adults.

Results: We included 666,024 hospitalizations of 615,446 unique patients who tested positive for a respiratory virus between October 01, 2020 and December 29, 2024.

Overall, the rate of hospitalizations associated with respiratory viruses increased more than 3-fold (+209.2%) between the last week of November and the last week of December 2024. By the last week of December, respiratory virus-associated hospitalizations accounted for 9.3% of all hospitalizations, up from 3.0% in late November. Influenza-associated hospitalizations increased by more than 8-fold. In the population 0-4 years of age, RSV-associated hospitalizations continue to be the respiratory virus associated with the most hospitalizations; at the end of December 7.5% of all hospitalizations in this population were associated with RSV. Within the population over 65 years old, hospitalizations associated with respiratory viruses also continue to increase and now account for 11.2% of all hospitalizations within this age group; an increase of 257.8%. Influenza- and RSV-associated hospitalizations increased the greatest amount (an increase of 875.8% and 287.2%), in the last month for this population.

Discussion: Hospitalizations associated with all monitored viruses have increased between the last week of November and the last week of December. These data highlight the continued rise in hospitalization associated with respiratory viruses, especially for hospitalizations associated with RSV and influenza. Although HMVP-

associated hospitalizations have increased, the trend is consistent with previous years. These data emphasize the need for continued surveillance and public health interventions, particularly in vulnerable populations such as young children and older adults.

Trends in surveillance

Overall population



	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
November 25, 2024	3.0%	1.0%	0.5%	0.1%	0.1%	0.7%	1.0%
December 23, 2024	9.3%	2.3%	4.3%	0.2%	0.2%	1.6%	1.2%
Change (percentage)	+209.2%	+141.5%	+790.0%	+84.7%	+67.0%	+144.9%	+16.4%
Difference (percentage points)	+6.3%	+1.4%	+3.8%	+0.1%	+0.1%	+1.0%	+0.2%



	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
November 25, 2024	6.3%	5.0%	5.8%	1.4%	3.3%	8.4%	19.1%
December 23, 2024	11.9%	6.6%	18.6%	1.3%	2.2%	10.5%	14.1%
Change (percentage)	+88.5%	+32.9%	+219.2%	-11.1%	-32.6%	+23.8%	-26.1%
Difference (percentage points)	+5.6%	+1.6%	+12.7%	-0.2%	-1.1%	+2.0%	-5.0%

In the week of December 23, 2024, respiratory virus-associated hospitalizations accounted for 9.3% of all hospitalizations, a dramatic increase from 3.0% at the end of November (+209.2%). The largest increases in hospitalization rates were observed for hospitalization associated with influenza (+790.0%), RSV (+144.9%), and COVID (+141.5%), while hospitalizations associated with human metapneumovirus (HMPV)

and parainfluenza showed more moderate increases (+84.7% and +67.0%, respectively). Rhinovirus-associated hospitalizations increased marginally (+16.4%). Influenza test positivity experienced the most substantial increase (+219.2%), followed by RSV (+23.8%) and COVID (+32.9%). Meanwhile, parainfluenza, rhinovirus, and HMPV test positivity declined (-32.6%, -26.1%, and -11.1%, respectively).

Infants and children (age 0-4)



	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
November 25, 2024	8.0%	2.1%	0.2%	0.1%	0.3%	5.1%	3.2%
December 23, 2024	10.7%	2.3%	0.9%	0.2%	0.3%	7.5%	2.5%
Change (percentage)	+33.7%	+8.3%	+284.5%	+92.2%	-2.4%	+48.7%	-21.8%
Difference (percentage points)	+2.7%	+0.2%	+0.7%	+0.1%	-0.0%	+2.5%	-0.7%



	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
November 25, 2024	14.1%	6.5%	5.7%	3.0%	8.0%	29.5%	40.9%
December 23, 2024	17.6%	6.2%	18.8%	2.5%	4.8%	31.8%	29.1%
Change (percentage)	+25.4%	-4.4%	+228.1%	-17.8%	-39.6%	+7.8%	-29.0%
Difference (percentage points)	+3.6%	-0.3%	+13.1%	-0.5%	-3.2%	+2.3%	-11.8%

In the population aged 0–4 years, respiratory virus-associated hospitalizations increased by 33.7% between the weeks of November 25 and December 23, 2024. RSV-associated hospitalizations saw a substantial rise for the third month in a row (+48.7%), now accounting for 7.5% of all hospitalizations within this age group. Influenza-associated hospitalizations experienced the largest increase (+284.5%), followed by HMPV (+92.2%). COVID-associated hospitalizations showed a modest rise (+8.3%), while parainfluenza-associated hospitalizations remained relatively stable (-2.4%). Rhinovirus-associated hospitalizations declined (-21.8%). By late December, 10.7% of all hospitalizations in this age group were associated with a respiratory virus. Influenza test positivity experienced the largest increase (+228.1%), followed by RSV (+7.8%). In contrast, test positivity rates for parainfluenza (-39.6%), rhinovirus (-29.0%), and HMPV (-17.8%) declined. COVID test positivity also decreased slightly (-4.4%). Despite its decline, rhinovirus remained prominent with a test positivity rate of 29.1% as of late December 2024. These trends highlight the continued burden of RSV, influenza, and other respiratory viruses in this vulnerable age group.

Older adults (age 65 and over)



	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
November 25, 2024	3.1%	1.2%	0.5%	0.1%	0.2%	0.4%	0.9%
December 23, 2024	11.2%	3.3%	5.2%	0.2%	0.3%	1.5%	1.1%
Change (percentage)	+257.8%	+168.9%	+875.8%	+157.2%	+63.9%	+287.3%	+22.8%
Difference (percentage points)	+8.1%	+2.1%	+4.7%	+0.1%	+0.1%	+1.1%	+0.2%



	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
November 25, 2024	3.9%	6.3%	2.7%	0.7%	1.7%	2.1%	9.2%
December 23, 2024	8.6%	9.2%	12.5%	1.2%	1.7%	4.5%	8.0%
Change (percentage)	+118.1%	+45.6%	+355.3%	+72.5%	+1.1%	+116.6%	-12.8%
Difference (percentage points)	+4.7%	+2.9%	+9.8%	+0.5%	+0.0%	+2.4%	-1.2%

Among older adults (age 65 and over), hospitalizations associated with respiratory viruses increased substantially, rising by 257.8% between the weeks of November 25 and December 23, 2024. Influenza-associated hospitalizations saw the most dramatic rise (+875.8%), followed by RSV- (+287.3%), COVID- (+168.9%), and HMPV-associated hospitalizations (+157.2%). Parainfluenza- and rhinovirus-associated hospitalizations also increased, though to a lesser extent (+63.9% and +22.8%, respectively). By late December, respiratory virus-associated hospitalizations accounted for 11.2% of all hospitalizations in this age group. Influenza test positivity experienced the largest increase (+355.3%), followed by RSV (+116.6%) and HMPV (+72.5%). COVID test positivity also rose (+45.6%). Parainfluenza test positivity remained stable (+1.1%), while rhinovirus test positivity declined slightly (-12.8%). These patterns highlight the evolving landscape of respiratory virus activity among older adults, with rising hospitalizations and test positivity for influenza, RSV, and COVID warranting close attention.

Introduction

COVID, influenza, and RSV account for a large proportion of hospitalizations related to respiratory illnesses in the United States. To provide a more complete understanding of hospitalizations related to respiratory viruses, we have also included other viruses known to cause respiratory illness such as human metapneumovirus (HMPV), parainfluenza, and rhinovirus. Each of these viruses can lead to hospitalization and death especially in vulnerable populations, such as infants, children, and older adults (Pastula et al., 2017; Shi et al., 2017, Centers for Disease Control and Prevention 2023a, Smits et al., 2023). Representative and timely data to proactively monitor infections are scarce.

Respiratory viruses are also a major source of infection and hospitalizations in older adults (defined here as patients 65 years of age or older). Incidence has been estimated between 3-10% annually for RSV in older adults (Boyce et al., 2000) and 8-10% for influenza in adults (Tokars et al., 2018). Often, as is the case with influenza, older adults are at higher risk for hospitalization and death than other age groups (Czaja et al. 2019). There are comorbidities that are associated with increased hospitalization risk for older adults, such as congestive heart failure and chronic lung disease (Lee et al., 2013). Further, asthma, COPD, and congestive heart failure can exacerbate respiratory virus infections. Here we report counts for a selection of high-risk medical conditions such as chronic lung diseases and asthma.

Incidence rates in infants and children (defined here as individuals less than five years of age) with respiratory virus infections are higher than other age groups, except adults 65 and older (Centers for Disease Control and Prevention, 2023c; Centers for Disease Control and Prevention, 2023d). In the future, we plan to include high-risk comorbid states, such as congenital heart disease, preterm birth, and cystic fibrosis (Committee on Infectious Diseases and Bronchiolitis Guidelines Committee et al., 2014).

It is important for public health experts and clinical providers to understand the trends in these infections to inform decisions about public health, clinical care, and public policy. Connecting population-level trends with granular clinical information available in Truveta Studio can be very useful to more deeply understand which cohorts are most impacted.

This report is intended to supplement the surveillance data provided by the CDC (Centers for Disease Control and Prevention, 2023b). This report includes additional independent data and clinical detail that is not captured in other reports.

Methods

Data

We evaluated respiratory virus-associated hospitalization trends of six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus between October 01, 2020 and December 29, 2024 using a subset of Truveta Data. Truveta provides access to continuously updated, linked, and de-identified electronic health record (EHR) from a collective of US health care systems that provide 18% of all daily clinical care in the US, including structured information on demographics, encounters, diagnoses, vital signs (e.g., weight, BMI, blood pressure), medication requests (prescriptions), medication administration, laboratory and diagnostic tests and results (e.g., COVID tests and values), and procedures. Updated EHR data are provided daily to Truveta by constituent health care systems. The data used in this study was provided on January 13, 2025 and included de-identified patient care data primarily located across ten states: New York, Florida, Virginia, California, Illinois, Ohio, Washington, North Carolina, Louisiana, and Arizona.

Population

We identified hospitalized patients who tested positive for one of the selected respiratory viruses within 14 days before or during the hospitalization. Positive lab results were identified using LOINC codes. Every respiratory virus-associated hospitalization has been grouped such that every hospitalization within 90 days is considered to be the same infection and thus only counted once. To align with seasonality in respiratory transmission, time periods include October 1st through September 30th of the following year.

Hospitalization rate analysis

Characteristics of respiratory virus-associated hospitalized patients were summarized, including demographics and comorbidities by respiratory virus season. Characteristics are provided for the overall population, individual viruses, and two at-risk sub populations: infants and children (age 0-4) and older adults (age 65 and over).

Respiratory virus-associated hospitalizations rates were summarized over time by virus. The hospitalization rate was calculated weekly as the number of patients with a respiratory virus associated hospitalization divided by the number of patients with a hospital admission in that week. Patients were included in this calculation on the first

day of their hospitalization. If their stay was greater than one day, they were not counted on subsequent dates.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Test positivity rate analysis

Lab results with known results were summarized over time by virus. The positivity rate was calculated monthly as the number of positive lab results divided by the total number of lab results with known results in that month.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Results

Overall population

Our study population consists of 666,024 hospitalizations of 615,446 unique patients (Table 1).

Table 1: Patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	175,854 (100.00%)	180,628 (100.00%)	125,570 (100.00%)	111,363 (100.00%)	22,031 (100.00%)	615,446 (100.00%)
Age Group						
< 6 months	1,274 (0.72%)	2,449 (1.36%)	3,075 (2.45%)	2,405 (2.16%)	589 (2.67%)	9,792 (1.59%)
6 - <12 months	504 (0.29%)	1,111 (0.62%)	1,461 (1.16%)	1,237 (1.11%)	384 (1.74%)	4,697 (0.76%)
1 - <2 years	899 (0.51%)	1,684 (0.93%)	2,040 (1.62%)	1,707 (1.53%)	621 (2.82%)	6,951 (1.13%)
2 - 4 years	1,050 (0.60%)	2,483 (1.37%)	3,137 (2.50%)	2,205 (1.98%)	776 (3.52%)	9,651 (1.57%)
5 - 17 years	1,848 (1.05%)	3,116 (1.73%)	3,558 (2.83%)	3,080 (2.77%)	910 (4.13%)	12,512 (2.03%)
18 - 49 years	39,963 (22.73%)	37,989 (21.03%)	17,443 (13.89%)	14,759 (13.25%)	3,111 (14.12%)	113,265 (18.40%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
50 - 64 years	44,310 (25.20%)	36,978 (20.47%)	19,807 (15.77%)	18,052 (16.21%)	3,567 (16.19%)	122,714 (19.94%)
65 - 74 years	36,591 (20.81%)	36,303 (20.10%)	24,670 (19.65%)	22,338 (20.06%)	4,139 (18.79%)	124,041 (20.15%)
75 - 84 years	31,335 (17.82%)	35,510 (19.66%)	29,122 (23.19%)	26,802 (24.07%)	4,731 (21.47%)	127,500 (20.72%)
85+ years	18,080 (10.28%)	23,005 (12.74%)	21,257 (16.93%)	18,778 (16.86%)	3,203 (14.54%)	84,323 (13.70%)
Sex						
Female	85,489 (48.61%)	92,479 (51.20%)	65,675 (52.30%)	57,980 (52.06%)	11,602 (52.66%)	313,225 (50.89%)
Male	88,644 (50.41%)	86,413 (47.84%)	58,832 (46.85%)	52,226 (46.90%)	10,263 (46.58%)	296,378 (48.16%)
Other	2 (0.00%)	2 (0.00%)	4 (0.00%)	0	0	8 (0.00%)
Unknown	1,719 (0.98%)	1,734 (0.96%)	1,059 (0.84%)	1,157 (1.04%)	166 (0.75%)	5,835 (0.95%)
Race						
White	111,878 (63.62%)	121,385 (67.20%)	83,948 (66.85%)	72,880 (65.44%)	14,120 (64.09%)	404,211 (65.68%)
Black or African American	21,752 (12.37%)	21,442 (11.87%)	13,975 (11.13%)	13,628 (12.24%)	3,111 (14.12%)	73,908 (12.01%)
Asian	4,422 (2.51%)	4,379 (2.42%)	4,184 (3.33%)	3,341 (3.00%)	641 (2.91%)	16,967 (2.76%)
Native Hawaiian or Other Pacific Islander	919 (0.52%)	959 (0.53%)	662 (0.53%)	641 (0.58%)	149 (0.68%)	3,330 (0.54%)
American Indian or Alaska Native	1,062 (0.60%)	1,110 (0.61%)	816 (0.65%)	658 (0.59%)	153 (0.69%)	3,799 (0.62%)
Other Race	12,453 (7.08%)	10,355 (5.73%)	8,424 (6.71%)	7,303 (6.56%)	1,774 (8.05%)	40,309 (6.55%)
Unknown	23,368 (13.29%)	20,998 (11.62%)	13,561 (10.80%)	12,912 (11.59%)	2,083 (9.45%)	72,922 (11.85%)
Ethnicity						
Hispanic or Latino	20,295 (11.54%)	16,674 (9.23%)	13,079 (10.42%)	12,637 (11.35%)	2,990 (13.57%)	65,675 (10.67%)
Not Hispanic or Latino	129,741 (73.78%)	142,106 (78.67%)	98,830 (78.71%)	88,442 (79.42%)	17,614 (79.95%)	476,733 (77.46%)
Unknown	25,818 (14.68%)	21,848 (12.10%)	13,661 (10.88%)	10,284 (9.23%)	1,427 (6.48%)	73,038 (11.87%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Virus						
COVID	164,866 (93.75%)	157,167 (87.01%)	76,493 (60.92%)	60,616 (54.43%)	7,741 (35.14%)	466,883 (75.86%)
HMPV	88 (0.05%)	2,230 (1.23%)	3,946 (3.14%)	3,211 (2.88%)	325 (1.48%)	9,800 (1.59%)
RSV	2,023 (1.15%)	4,372 (2.42%)	7,889 (6.28%)	9,564 (8.59%)	3,013 (13.68%)	26,861 (4.36%)
influenza	398 (0.23%)	4,783 (2.65%)	17,272 (13.75%)	19,858 (17.83%)	5,387 (24.45%)	47,698 (7.75%)
parainfluenza	1,466 (0.83%)	2,380 (1.32%)	4,338 (3.45%)	3,647 (3.27%)	761 (3.45%)	12,592 (2.05%)
rhinovirus	7,013 (3.99%)	9,696 (5.37%)	15,632 (12.45%)	14,467 (12.99%)	4,804 (21.81%)	51,612 (8.39%)
Comorbidity						
Asthma	14,630 (8.32%)	17,826 (9.87%)	15,123 (12.04%)	14,649 (13.15%)	3,380 (15.34%)	65,608 (10.66%)
Chronic Lung Disease	11,123 (6.33%)	12,026 (6.66%)	9,463 (7.54%)	9,175 (8.24%)	1,945 (8.83%)	43,732 (7.11%)
Chronic Obstructive Pulmonary Disease	19,652 (11.18%)	26,717 (14.79%)	22,084 (17.59%)	21,316 (19.14%)	4,299 (19.51%)	94,068 (15.28%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations is shown in Figure 1. Figure 2 shows the same data stacked to represent the combined impact of the viruses.

Figure 1: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020



Figure 2: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020



Test positivity rate over time

We included 47,601,215 lab results with known results of which 4,465,294 were positive. The test positivity rate is shown in Figure 3.

Figure 3: Weekly test positivity rate since October 2020



COVID-19

Our COVID study population consists of 483,251 hospitalizations of 466,883 unique patients (Table 2).

Table 2: COVID patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	164,866 (100.00%)	157,167 (100.00%)	76,493 (100.00%)	60,616 (100.00%)	7,741 (100.00%)	466,883 (100.00%)
Age Group						
< 6 months	311 (0.19%)	760 (0.48%)	426 (0.56%)	371 (0.61%)	116 (1.50%)	1,984 (0.42%)
6 - <12 months	57 (0.03%)	269 (0.17%)	215 (0.28%)	233 (0.38%)	75 (0.97%)	849 (0.18%)
1 - <2 years	104 (0.06%)	277 (0.18%)	196 (0.26%)	270 (0.45%)	161 (2.08%)	1,008 (0.22%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
2 - 4 years	132 (0.08%)	420 (0.27%)	267 (0.35%)	316 (0.52%)	210 (2.71%)	1,345 (0.29%)
5 - 17 years	933 (0.57%)	1,390 (0.88%)	592 (0.77%)	669 (1.10%)	317 (4.10%)	3,901 (0.84%)
18 - 49 years	38,008 (23.05%)	34,578 (22.00%)	9,994 (13.07%)	6,530 (10.77%)	701 (9.06%)	89,811 (19.24%)
50 - 64 years	42,592 (25.83%)	33,549 (21.35%)	11,644 (15.22%)	8,750 (14.44%)	933 (12.05%)	97,468 (20.88%)
65 - 74 years	35,180 (21.34%)	32,746 (20.84%)	16,154 (21.12%)	12,905 (21.29%)	1,476 (19.07%)	98,461 (21.09%)
75 - 84 years	30,162 (18.29%)	32,274 (20.53%)	20,914 (27.34%)	17,577 (29.00%)	2,170 (28.03%)	103,097 (22.08%)
85+ years	17,387 (10.55%)	20,904 (13.30%)	16,091 (21.04%)	12,995 (21.44%)	1,582 (20.44%)	68,959 (14.77%)
Sex						
Female	79,883 (48.45%)	80,340 (51.12%)	39,479 (51.61%)	30,754 (50.74%)	3,923 (50.68%)	234,379 (50.20%)
Male	83,355 (50.56%)	75,289 (47.90%)	36,336 (47.50%)	29,169 (48.12%)	3,741 (48.33%)	227,890 (48.81%)
Other	2 (0.00%)	2 (0.00%)	2 (0.00%)	0	0	6 (0.00%)
Unknown	1,626 (0.99%)	1,536 (0.98%)	676 (0.88%)	693 (1.14%)	77 (0.99%)	4,608 (0.99%)
Race						
White	105,375 (63.92%)	106,650 (67.86%)	52,950 (69.22%)	41,135 (67.86%)	5,191 (67.06%)	311,301 (66.68%)
Black or African American	19,997 (12.13%)	18,297 (11.64%)	7,666 (10.02%)	6,541 (10.79%)	876 (11.32%)	53,377 (11.43%)
Asian	4,065 (2.47%)	3,501 (2.23%)	2,308 (3.02%)	1,876 (3.09%)	296 (3.82%)	12,046 (2.58%)
Native Hawaiian or Other Pacific Islander	848 (0.51%)	750 (0.48%)	299 (0.39%)	278 (0.46%)	26 (0.34%)	2,201 (0.47%)
American Indian or Alaska Native	991 (0.60%)	940 (0.60%)	411 (0.54%)	336 (0.55%)	48 (0.62%)	2,726 (0.58%)
Other Race	11,274 (6.84%)	8,263 (5.26%)	4,135 (5.41%)	3,127 (5.16%)	542 (7.00%)	27,341 (5.86%)
Unknown	22,316 (13.54%)	18,766 (11.94%)	8,724 (11.40%)	7,323 (12.08%)	762 (9.84%)	57,891 (12.40%)
Ethnicity						

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Hispanic or Latino	18,926 (11.48%)	13,690 (8.71%)	6,295 (8.23%)	5,455 (9.00%)	731 (9.44%)	45,097 (9.66%)
Not Hispanic or Latino	121,290 (73.57%)	123,862 (78.81%)	61,064 (79.83%)	49,056 (80.93%)	6,416 (82.88%)	361,688 (77.47%)
Unknown	24,650 (14.95%)	19,615 (12.48%)	9,134 (11.94%)	6,105 (10.07%)	594 (7.67%)	60,098 (12.87%)
Comorbidity						
Asthma	12,837 (7.79%)	14,192 (9.03%)	7,547 (9.87%)	6,738 (11.12%)	976 (12.61%)	42,290 (9.06%)
Chronic Lung Disease	10,185 (6.18%)	10,068 (6.41%)	5,367 (7.02%)	4,779 (7.88%)	623 (8.05%)	31,022 (6.64%)
Chronic Obstructive Pulmonary Disease	17,824 (10.81%)	22,592 (14.37%)	13,039 (17.05%)	11,595 (19.13%)	1,491 (19.26%)	66,541 (14.25%)

Hospitalization rate over time

The rate of COVID-associated hospitalization is shown in Figure 4. Figure 5 shows seasonal trends.

Figure 4: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions since October 2020



Figure 5: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 26,527,094 COVID lab results with known results of which 3,138,567 were positive. The COVID test positivity rate is shown in Figure 6. Figure 7 shows yearly trends.

Figure 6: Weekly COVID test positivity rate since October 2020



Figure 7: Weekly COVID test positivity rate by season



Influenza

Our influenza study population consists of 55,097 hospitalizations of 47,698 unique patients (Table 3).

Table 3: Influenza patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	398 (100.00%)	4,783 (100.00%)	17,272 (100.00%)	19,858 (100.00%)	5,387 (100.00%)	47,698 (100.00%)
Age Group						
< 6 months	2 (0.50%)	27 (0.56%)	78 (0.45%)	88 (0.44%)	14 (0.26%)	209 (0.44%)
6 - <12 months	1 (0.25%)	17 (0.36%)	65 (0.38%)	48 (0.24%)	12 (0.22%)	143 (0.30%)
1 - <2 years	0	29 (0.61%)	120 (0.69%)	83 (0.42%)	24 (0.45%)	256 (0.54%)
2 - 4 years	3 (0.75%)	59 (1.23%)	258 (1.49%)	199 (1.00%)	36 (0.67%)	555 (1.16%)
5 - 17 years	6 (1.51%)	177 (3.70%)	575 (3.33%)	516 (2.60%)	108 (2.00%)	1,382 (2.90%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
18 - 49 years	111 (27.89%)	1,073 (22.43%)	3,421 (19.81%)	4,055 (20.42%)	921 (17.10%)	9,581 (20.09%)
50 - 64 years	101 (25.38%)	881 (18.42%)	3,580 (20.73%)	4,432 (22.32%)	1,154 (21.42%)	10,148 (21.28%)
65 - 74 years	70 (17.59%)	966 (20.20%)	3,709 (21.47%)	4,270 (21.50%)	1,188 (22.05%)	10,203 (21.39%)
75 - 84 years	74 (18.59%)	940 (19.65%)	3,465 (20.06%)	4,001 (20.15%)	1,190 (22.09%)	9,670 (20.27%)
85+ years	30 (7.54%)	614 (12.84%)	2,001 (11.59%)	2,166 (10.91%)	740 (13.74%)	5,551 (11.64%)
Sex						
Female	243 (61.06%)	2,690 (56.24%)	9,640 (55.81%)	10,830 (54.54%)	3,023 (56.12%)	26,426 (55.40%)
Male	150 (37.69%)	2,045 (42.76%)	7,504 (43.45%)	8,855 (44.59%)	2,334 (43.33%)	20,888 (43.79%)
Other	0	0	2 (0.01%)	0	0	2 (0.00%)
Unknown	5 (1.26%)	48 (1.00%)	126 (0.73%)	173 (0.87%)	30 (0.56%)	382 (0.80%)
Race						
White	254 (63.82%)	3,199 (66.88%)	11,427 (66.16%)	12,672 (63.81%)	3,427 (63.62%)	30,979 (64.95%)
Black or African American	73 (18.34%)	675 (14.11%)	2,386 (13.81%)	3,079 (15.51%)	832 (15.44%)	7,045 (14.77%)
Asian	6 (1.51%)	102 (2.13%)	451 (2.61%)	517 (2.60%)	128 (2.38%)	1,204 (2.52%)
Native Hawaiian or Other Pacific Islander	2 (0.50%)	42 (0.88%)	114 (0.66%)	151 (0.76%)	31 (0.58%)	340 (0.71%)
American Indian or Alaska Native	2 (0.50%)	41 (0.86%)	150 (0.87%)	131 (0.66%)	42 (0.78%)	366 (0.77%)
Other Race	13 (3.27%)	248 (5.19%)	1,097 (6.35%)	1,303 (6.56%)	435 (8.07%)	3,096 (6.49%)
Unknown	48 (12.06%)	476 (9.95%)	1,647 (9.54%)	2,005 (10.10%)	492 (9.13%)	4,668 (9.79%)
Ethnicity						
Hispanic or Latino	32 (8.04%)	484 (10.12%)	2,011 (11.64%)	2,431 (12.24%)	780 (14.48%)	5,738 (12.03%)
Not Hispanic or Latino	306 (76.88%)	3,830 (80.08%)	13,711 (79.38%)	15,870 (79.92%)	4,276 (79.38%)	37,993 (79.65%)
Unknown	60 (15.08%)	469 (9.81%)	1,550 (8.97%)	1,557 (7.84%)	331 (6.14%)	3,967 (8.32%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Comorbidity						
Asthma	36 (9.05%)	724 (15.14%)	2,643 (15.30%)	3,036 (15.29%)	888 (16.48%)	7,327 (15.36%)
Chronic Lung Disease	28 (7.04%)	428 (8.95%)	1,523 (8.82%)	1,821 (9.17%)	485 (9.00%)	4,285 (8.98%)
Chronic Obstructive Pulmonary Disease	66 (16.58%)	1,034 (21.62%)	3,667 (21.23%)	4,093 (20.61%)	1,078 (20.01%)	9,938 (20.84%)

Hospitalization rate over time

The rate of influenza-associated hospitalization is shown in Figure 8. Figure 9 shows seasonal trends.

Figure 8: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions since October 2020



Figure 9: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 11,457,556 influenza lab results with known results of which 761,454 were positive. The influenza test positivity rate is shown in Figure 10. Figure 11 shows yearly trends.

Figure 10: Weekly influenza test positivity rate since October 2020

Figure 11: Weekly influenza test positivity rate by season



Human metapneumovirus (HMPV)

Our HMPV study population consists of 13,911 hospitalizations of 9,800 unique patients (Table 4).

Table 4: HMPV patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	88 (100.00%)	2,230 (100.00%)	3,946 (100.00%)	3,211 (100.00%)	325 (100.00%)	9,800 (100.00%)
Age Group						
< 6 months	2 (2.27%)	56 (2.51%)	133 (3.37%)	68 (2.12%)	3 (0.92%)	262 (2.67%)
6 - <12 months	1 (1.14%)	67 (3.00%)	97 (2.46%)	77 (2.40%)	10 (3.08%)	252 (2.57%)
1 - <2 years	8 (9.09%)	120 (5.38%)	142 (3.60%)	79 (2.46%)	7 (2.15%)	356 (3.63%)
2 - 4 years	12 (13.64%)	181 (8.12%)	234 (5.93%)	127 (3.96%)	11 (3.38%)	565 (5.77%)
5 - 17 years	2 (2.27%)	96 (4.30%)	139 (3.52%)	93 (2.90%)	9 (2.77%)	339 (3.46%)
18 - 49 years	12 (13.64%)	261 (11.70%)	419 (10.62%)	390 (12.15%)	40 (12.31%)	1,122 (11.45%)
50 - 64 years	20 (22.73%)	398 (17.85%)	659 (16.70%)	570 (17.75%)	53 (16.31%)	1,700 (17.35%)
65 - 74 years	8 (9.09%)	403 (18.07%)	767 (19.44%)	657 (20.46%)	57 (17.54%)	1,892 (19.31%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
75 - 84 years	14 (15.91%)	412 (18.48%)	828 (20.98%)	709 (22.08%)	80 (24.62%)	2,043 (20.85%)
85+ years	9 (10.23%)	236 (10.58%)	528 (13.38%)	441 (13.73%)	55 (16.92%)	1,269 (12.95%)
Sex						
Female	41 (46.59%)	1,272 (57.04%)	2,286 (57.93%)	1,960 (61.04%)	194 (59.69%)	5,753 (58.70%)
Male	45 (51.14%)	942 (42.24%)	1,640 (41.56%)	1,226 (38.18%)	129 (39.69%)	3,982 (40.63%)
Unknown	2 (2.27%)	16 (0.72%)	20 (0.51%)	25 (0.78%)	2 (0.62%)	65 (0.66%)
Race						
White	58 (65.91%)	1,612 (72.29%)	2,803 (71.03%)	2,135 (66.49%)	228 (70.15%)	6,836 (69.76%)
Black or African American	8 (9.09%)	230 (10.31%)	349 (8.84%)	361 (11.24%)	37 (11.38%)	985 (10.05%)
Asian	1 (1.14%)	47 (2.11%)	117 (2.97%)	73 (2.27%)	7 (2.15%)	245 (2.50%)
Native Hawaiian or Other Pacific Islander	0	16 (0.72%)	14 (0.35%)	8 (0.25%)	0	38 (0.39%)
American Indian or Alaska Native	0	12 (0.54%)	34 (0.86%)	18 (0.56%)	3 (0.92%)	67 (0.68%)
Other Race	9 (10.23%)	111 (4.98%)	290 (7.35%)	260 (8.10%)	29 (8.92%)	699 (7.13%)
Unknown	12 (13.64%)	202 (9.06%)	339 (8.59%)	356 (11.09%)	21 (6.46%)	930 (9.49%)
Ethnicity						
Hispanic or Latino	19 (21.59%)	225 (10.09%)	546 (13.84%)	492 (15.32%)	56 (17.23%)	1,338 (13.65%)
Not Hispanic or Latino	55 (62.50%)	1,785 (80.04%)	3,100 (78.56%)	2,475 (77.08%)	254 (78.15%)	7,669 (78.26%)
Unknown	14 (15.91%)	220 (9.87%)	300 (7.60%)	244 (7.60%)	15 (4.62%)	793 (8.09%)
Comorbidity						
Asthma	11 (12.50%)	342 (15.34%)	614 (15.56%)	504 (15.70%)	49 (15.08%)	1,520 (15.51%)
Chronic Lung Disease	10 (11.36%)	259 (11.61%)	413 (10.47%)	311 (9.69%)	43 (13.23%)	1,036 (10.57%)
Chronic Obstructive Pulmonary Disease	17 (19.32%)	484 (21.70%)	800 (20.27%)	621 (19.34%)	71 (21.85%)	1,993 (20.34%)

Hospitalization rate over time

The rate of HMPV-associated hospitalization is shown in Figure 12. Figure 13 shows seasonal trends.

Figure 12: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions since October 2020



Figure 13: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 1,507,236 HMPV lab results with known results of which 37,833 were positive. The HMPV test positivity rate is shown in Figure 14. Figure 15 shows yearly trends.

Figure 14: Weekly HMPV test positivity rate since October 2020

Figure 15: Weekly HMPV test positivity rate by season



Parainfluenza virus

Our parainfluenza study population consists of 15,364 hospitalizations of 12,592 unique patients (Table 5).

Table 5: Parainfluenza patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	1,466 (100.00%)	2,380 (100.00%)	4,338 (100.00%)	3,647 (100.00%)	761 (100.00%)	12,592 (100.00%)
Age Group						
< 6 months	81 (5.53%)	123 (5.17%)	210 (4.84%)	120 (3.29%)	16 (2.10%)	550 (4.37%)
6 - <12 months	62 (4.23%)	89 (3.74%)	146 (3.37%)	79 (2.17%)	9 (1.18%)	385 (3.06%)
1 - <2 years	99 (6.75%)	117 (4.92%)	170 (3.92%)	132 (3.62%)	26 (3.42%)	544 (4.32%)
2 - 4 years	116 (7.91%)	201 (8.45%)	258 (5.95%)	149 (4.09%)	32 (4.20%)	756 (6.00%)
5 - 17 years	89 (6.07%)	127 (5.34%)	215 (4.96%)	122 (3.35%)	35 (4.60%)	588 (4.67%)
18 - 49 years	196 (13.37%)	297 (12.48%)	485 (11.18%)	397 (10.89%)	113 (14.85%)	1,488 (11.82%)
50 - 64 years	261 (17.80%)	404 (16.97%)	730 (16.83%)	665 (18.23%)	119 (15.64%)	2,179 (17.30%)
65 - 74 years	232 (15.83%)	414 (17.39%)	747 (17.22%)	711 (19.50%)	169 (22.21%)	2,273 (18.05%)
75 - 84 years	213 (14.53%)	351 (14.75%)	816 (18.81%)	787 (21.58%)	144 (18.92%)	2,311 (18.35%)
85+ years	117 (7.98%)	257 (10.80%)	561 (12.93%)	485 (13.30%)	98 (12.88%)	1,518 (12.06%)
Sex						
Female	758 (51.71%)	1,312 (55.13%)	2,333 (53.78%)	1,983 (54.37%)	423 (55.58%)	6,809 (54.07%)
Male	694 (47.34%)	1,051 (44.16%)	1,965 (45.30%)	1,625 (44.56%)	334 (43.89%)	5,669 (45.02%)
Unknown	14 (0.95%)	17 (0.71%)	40 (0.92%)	39 (1.07%)	4 (0.53%)	114 (0.91%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Race						
White	910 (62.07%)	1,479 (62.14%)	2,732 (62.98%)	2,288 (62.74%)	504 (66.23%)	7,913 (62.84%)
Black or African American	198 (13.51%)	289 (12.14%)	491 (11.32%)	443 (12.15%)	103 (13.53%)	1,524 (12.10%)
Asian	42 (2.86%)	98 (4.12%)	191 (4.40%)	107 (2.93%)	15 (1.97%)	453 (3.60%)
Native Hawaiian or Other Pacific Islander	5 (0.34%)	12 (0.50%)	20 (0.46%)	27 (0.74%)	1 (0.13%)	65 (0.52%)
American Indian or Alaska Native	14 (0.95%)	18 (0.76%)	36 (0.83%)	24 (0.66%)	2 (0.26%)	94 (0.75%)
Other Race	150 (10.23%)	231 (9.71%)	440 (10.14%)	328 (8.99%)	62 (8.15%)	1,211 (9.62%)
Unknown	147 (10.03%)	253 (10.63%)	428 (9.87%)	430 (11.79%)	74 (9.72%)	1,332 (10.58%)
Ethnicity						
Hispanic or Latino	159 (10.85%)	302 (12.69%)	569 (13.12%)	542 (14.86%)	115 (15.11%)	1,687 (13.40%)
Not Hispanic or Latino	1,141 (77.83%)	1,820 (76.47%)	3,345 (77.11%)	2,822 (77.38%)	603 (79.24%)	9,731 (77.28%)
Unknown	166 (11.32%)	258 (10.84%)	424 (9.77%)	283 (7.76%)	43 (5.65%)	1,174 (9.32%)
Comorbidity						
Asthma	228 (15.55%)	372 (15.63%)	685 (15.79%)	572 (15.68%)	128 (16.82%)	1,985 (15.76%)
Chronic Lung Disease	141 (9.62%)	257 (10.80%)	423 (9.75%)	410 (11.24%)	82 (10.78%)	1,313 (10.43%)
Chronic Obstructive Pulmonary Disease	311 (21.21%)	497 (20.88%)	909 (20.95%)	848 (23.25%)	199 (26.15%)	2,764 (21.95%)

Hospitalization rate over time

The rate of parainfluenza-associated hospitalization is shown in Figure 16. Figure 17 shows seasonal trends.

Figure 16: Rate of weekly parainfluenza-associated hospitalizations compared to all hospital admissions since October 2020

Figure 17: Rate of weekly parainfluenza-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 1,587,614 parainfluenza lab results with known results of which 59,950 were positive. The parainfluenza test positivity rate is shown in Figure 18. Figure 19 shows yearly trends.

Figure 18: Weekly parainfluenza test positivity rate since October 2020

Figure 19: Weekly parainfluenza test positivity rate by season



Respiratory syncytial virus (RSV)

Our RSV study population consists of 34,184 hospitalizations of 26,861 unique patients (Table 6).

Table 6: RSV patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	2,023 (100.00%)	4,372 (100.00%)	7,889 (100.00%)	9,564 (100.00%)	3,013 (100.00%)	26,861 (100.00%)
Age Group						
< 6 months	501 (24.77%)	791 (18.09%)	1,378 (17.47%)	1,077 (11.26%)	274 (9.09%)	4,021 (14.97%)
6 - <12 months	135 (6.67%)	287 (6.56%)	498 (6.31%)	428 (4.48%)	185 (6.14%)	1,533 (5.71%)
1 - <2 years	184 (9.10%)	354 (8.10%)	561 (7.11%)	459 (4.80%)	227 (7.53%)	1,785 (6.65%)
2 - 4 years	162 (8.01%)	371 (8.49%)	715 (9.06%)	413 (4.32%)	240 (7.97%)	1,901 (7.08%)
5 - 17 years	47 (2.32%)	123 (2.81%)	247 (3.13%)	219 (2.29%)	85 (2.82%)	721 (2.68%)
18 - 49 years	186 (9.19%)	382 (8.74%)	597 (7.57%)	831 (8.69%)	331 (10.99%)	2,327 (8.66%)
50 - 64 years	260 (12.85%)	525 (12.01%)	893 (11.32%)	1,397 (14.61%)	442 (14.67%)	3,517 (13.09%)
65 - 74 years	240 (11.86%)	560 (12.81%)	1,072 (13.59%)	1,588 (16.60%)	459 (15.23%)	3,919 (14.59%)
75 - 84 years	189 (9.34%)	588 (13.45%)	1,132 (14.35%)	1,787 (18.68%)	464 (15.40%)	4,160 (15.49%)
85+ years	119 (5.88%)	391 (8.94%)	796 (10.09%)	1,365 (14.27%)	306 (10.16%)	2,977 (11.08%)
Sex						

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Female	1,076 (53.19%)	2,234 (51.10%)	4,206 (53.31%)	5,223 (54.61%)	1,630 (54.10%)	14,369 (53.49%)
Male	939 (46.42%)	2,106 (48.17%)	3,615 (45.82%)	4,258 (44.52%)	1,365 (45.30%)	12,283 (45.73%)
Unknown	8 (0.40%)	32 (0.73%)	68 (0.86%)	83 (0.87%)	18 (0.60%)	209 (0.78%)
Race						
White	1,187 (58.68%)	2,794 (63.91%)	5,005 (63.44%)	6,187 (64.69%)	1,755 (58.25%)	16,928 (63.02%)
Black or African American	373 (18.44%)	525 (12.01%)	851 (10.79%)	1,090 (11.40%)	487 (16.16%)	3,326 (12.38%)
Asian	52 (2.57%)	194 (4.44%)	427 (5.41%)	353 (3.69%)	105 (3.48%)	1,131 (4.21%)
Native Hawaiian or Other Pacific Islander	17 (0.84%)	76 (1.74%)	146 (1.85%)	106 (1.11%)	74 (2.46%)	419 (1.56%)
American Indian or Alaska Native	15 (0.74%)	36 (0.82%)	64 (0.81%)	72 (0.75%)	21 (0.70%)	208 (0.77%)
Other Race	181 (8.95%)	334 (7.64%)	668 (8.47%)	643 (6.72%)	262 (8.70%)	2,088 (7.77%)
Unknown	198 (9.79%)	413 (9.45%)	728 (9.23%)	1,113 (11.64%)	309 (10.26%)	2,761 (10.28%)
Ethnicity						
Hispanic or Latino	280 (13.84%)	591 (13.52%)	1,197 (15.17%)	1,245 (13.02%)	520 (17.26%)	3,833 (14.27%)
Not Hispanic or Latino	1,526 (75.43%)	3,383 (77.38%)	5,977 (75.76%)	7,453 (77.93%)	2,311 (76.70%)	20,650 (76.88%)
Unknown	217 (10.73%)	398 (9.10%)	715 (9.06%)	866 (9.05%)	182 (6.04%)	2,378 (8.85%)
Comorbidity						
Asthma	229 (11.32%)	562 (12.85%)	1,010 (12.80%)	1,330 (13.91%)	453 (15.03%)	3,584 (13.34%)
Chronic Lung Disease	130 (6.43%)	296 (6.77%)	548 (6.95%)	762 (7.97%)	222 (7.37%)	1,958 (7.29%)
Chronic Obstructive Pulmonary Disease	273 (13.49%)	711 (16.26%)	1,318 (16.71%)	1,892 (19.78%)	489 (16.23%)	4,683 (17.43%)

Hospitalization rate over time

The rate of RSV-associated hospitalization is shown in Figure 20. Figure 21 shows seasonal trends.

Figure 20: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions since October 2020



Figure 21: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 5,043,179 RSV lab results with known results of which 227,511 were positive. The RSV test positivity rate is shown in Figure 22. Figure 23 shows yearly trends.

Figure 22: Weekly RSV test positivity rate since October 2020



Figure 23: Weekly RSV test positivity rate by season



Rhinovirus

Our rhinovirus study population consists of 64,217 hospitalizations of 51,612 unique patients (Table 7).

Table 7: Rhinovirus patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	7,013 (100.00%)	9,696 (100.00%)	15,632 (100.00%)	14,467 (100.00%)	4,804 (100.00%)	51,612 (100.00%)
Age Group						
< 6 months	377 (5.38%)	692 (7.14%)	850 (5.44%)	681 (4.71%)	166 (3.46%)	2,766 (5.36%)
6 - <12 months	248 (3.54%)	382 (3.94%)	440 (2.81%)	372 (2.57%)	93 (1.94%)	1,535 (2.97%)
1 - <2 years	504 (7.19%)	787 (8.12%)	851 (5.44%)	684 (4.73%)	176 (3.66%)	3,002 (5.82%)
2 - 4 years	625 (8.91%)	1,251 (12.90%)	1,405 (8.99%)	1,001 (6.92%)	247 (5.14%)	4,529 (8.78%)
5 - 17 years	771 (10.99%)	1,203 (12.41%)	1,790 (11.45%)	1,461 (10.10%)	356 (7.41%)	5,581 (10.81%)
18 - 49 years	1,450 (20.68%)	1,398 (14.42%)	2,527 (16.17%)	2,556 (17.67%)	1,005 (20.92%)	8,936 (17.31%)
50 - 64 years	1,076 (15.34%)	1,221 (12.59%)	2,301 (14.72%)	2,238 (15.47%)	866 (18.03%)	7,702 (14.92%)
65 - 74 years	861 (12.28%)	1,214 (12.52%)	2,221 (14.21%)	2,207 (15.26%)	790 (16.44%)	7,293 (14.13%)
75 - 84 years	683 (9.74%)	945 (9.75%)	1,967 (12.58%)	1,941 (13.42%)	683 (14.22%)	6,219 (12.05%)
85+ years	418 (5.96%)	603 (6.22%)	1,280 (8.19%)	1,326 (9.17%)	422 (8.78%)	4,049 (7.85%)
Sex						

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Female	3,488 (49.74%)	4,631 (47.76%)	7,731 (49.46%)	7,230 (49.98%)	2,409 (50.15%)	25,489 (49.39%)
Male	3,461 (49.35%)	4,980 (51.36%)	7,772 (49.72%)	7,093 (49.03%)	2,360 (49.13%)	25,666 (49.73%)
Unknown	64 (0.91%)	85 (0.88%)	129 (0.83%)	144 (1.00%)	35 (0.73%)	457 (0.89%)
Race						
White	4,094 (58.38%)	5,651 (58.28%)	9,031 (57.77%)	8,463 (58.50%)	3,015 (62.76%)	30,254 (58.62%)
Black or African American	1,103 (15.73%)	1,426 (14.71%)	2,232 (14.28%)	2,114 (14.61%)	776 (16.15%)	7,651 (14.82%)
Asian	256 (3.65%)	437 (4.51%)	690 (4.41%)	415 (2.87%)	90 (1.87%)	1,888 (3.66%)
Native Hawaiian or Other Pacific Islander	47 (0.67%)	63 (0.65%)	69 (0.44%)	71 (0.49%)	17 (0.35%)	267 (0.52%)
American Indian or Alaska Native	40 (0.57%)	63 (0.65%)	121 (0.77%)	77 (0.53%)	37 (0.77%)	338 (0.65%)
Other Race	826 (11.78%)	1,168 (12.05%)	1,794 (11.48%)	1,642 (11.35%)	444 (9.24%)	5,874 (11.38%)
Unknown	647 (9.23%)	888 (9.16%)	1,695 (10.84%)	1,685 (11.65%)	425 (8.85%)	5,340 (10.35%)
Ethnicity						
Hispanic or Latino	879 (12.53%)	1,382 (14.25%)	2,461 (15.74%)	2,472 (17.09%)	788 (16.40%)	7,982 (15.47%)
Not Hispanic or Latino	5,423 (77.33%)	7,426 (76.59%)	11,633 (74.42%)	10,766 (74.42%)	3,754 (78.14%)	39,002 (75.57%)
Unknown	711 (10.14%)	888 (9.16%)	1,538 (9.84%)	1,229 (8.50%)	262 (5.45%)	4,628 (8.97%)
Comorbidity						
Asthma	1,289 (18.38%)	1,634 (16.85%)	2,624 (16.79%)	2,469 (17.07%)	886 (18.44%)	8,902 (17.25%)
Chronic Lung Disease	629 (8.97%)	718 (7.41%)	1,189 (7.61%)	1,092 (7.55%)	490 (10.20%)	4,118 (7.98%)
Chronic Obstructive Pulmonary Disease	1,161 (16.55%)	1,399 (14.43%)	2,351 (15.04%)	2,267 (15.67%)	971 (20.21%)	8,149 (15.79%)

Hospitalization rate over time

The rate of rhinovirus-associated hospitalization is shown in Figure 24. Figure 25 shows seasonal trends.

Figure 24: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions since October 2020

Figure 25: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 1,478,536 rhinovirus lab results with known results of which 239,979 were positive. The rhinovirus test positivity rate is shown in Figure 26. Figure 27 shows yearly trends.

Figure 26: Weekly rhinovirus test positivity rate since October 2020

Figure 27: Weekly rhinovirus test positivity rate by season



Infants and children (age 0-4)

Our infants and children study population consists of 40,881 hospitalizations of 31,091 unique patients (Table 8).

Table 8: Infants and children patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	3,727 (100.00%)	7,727 (100.00%)	9,713 (100.00%)	7,554 (100.00%)	2,370 (100.00%)	31,091 (100.00%)
Age Group						
< 6 months	1,274 (34.18%)	2,449 (31.69%)	3,075 (31.66%)	2,405 (31.84%)	589 (24.85%)	9,792 (31.49%)
6 - <12 months	504 (13.52%)	1,111 (14.38%)	1,461 (15.04%)	1,237 (16.38%)	384 (16.20%)	4,697 (15.11%)
1 - <2 years	899 (24.12%)	1,684 (21.79%)	2,040 (21.00%)	1,707 (22.60%)	621 (26.20%)	6,951 (22.36%)
2 - 4 years	1,050 (28.17%)	2,483 (32.13%)	3,137 (32.30%)	2,205 (29.19%)	776 (32.74%)	9,651 (31.04%)
Sex						
Female	1,567 (42.04%)	3,208 (41.52%)	4,210 (43.34%)	3,269 (43.28%)	1,003 (42.32%)	13,257 (42.64%)
Male	2,159 (57.93%)	4,505 (58.30%)	5,493 (56.55%)	4,271 (56.54%)	1,365 (57.59%)	17,793 (57.23%)
Unknown	1 (0.03%)	14 (0.18%)	10 (0.10%)	14 (0.19%)	2 (0.08%)	41 (0.13%)
Race						
White	1,730 (46.42%)	3,718 (48.12%)	4,531 (46.65%)	3,404 (45.06%)	1,053 (44.43%)	14,436 (46.43%)
Black or African American	736 (19.75%)	1,298 (16.80%)	1,491 (15.35%)	1,181 (15.63%)	422 (17.81%)	5,128 (16.49%)
Asian	184 (4.94%)	506 (6.55%)	795 (8.18%)	485 (6.42%)	136 (5.74%)	2,106 (6.77%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Native Hawaiian or Other Pacific Islander	72 (1.93%)	171 (2.21%)	204 (2.10%)	192 (2.54%)	74 (3.12%)	713 (2.29%)
American Indian or Alaska Native	31 (0.83%)	71 (0.92%)	118 (1.21%)	57 (0.75%)	16 (0.68%)	293 (0.94%)
Other Race	687 (18.43%)	1,256 (16.25%)	1,596 (16.43%)	1,214 (16.07%)	410 (17.30%)	5,163 (16.61%)
Unknown	287 (7.70%)	707 (9.15%)	978 (10.07%)	1,021 (13.52%)	259 (10.93%)	3,252 (10.46%)
Ethnicity						
Hispanic or Latino	761 (20.42%)	1,634 (21.15%)	2,415 (24.86%)	1,898 (25.13%)	597 (25.19%)	7,305 (23.50%)
Not Hispanic or Latino	2,675 (71.77%)	5,546 (71.77%)	6,560 (67.54%)	5,074 (67.17%)	1,615 (68.14%)	21,470 (69.06%)
Unknown	291 (7.81%)	547 (7.08%)	738 (7.60%)	582 (7.70%)	158 (6.67%)	2,316 (7.45%)
Virus						
COVID	604 (16.21%)	1,726 (22.34%)	1,104 (11.37%)	1,190 (15.75%)	562 (23.71%)	5,186 (16.68%)
HMPV	23 (0.62%)	424 (5.49%)	606 (6.24%)	351 (4.65%)	31 (1.31%)	1,435 (4.62%)
RSV	982 (26.35%)	1,803 (23.33%)	3,152 (32.45%)	2,377 (31.47%)	926 (39.07%)	9,240 (29.72%)
influenza	6 (0.16%)	132 (1.71%)	521 (5.36%)	418 (5.53%)	86 (3.63%)	1,163 (3.74%)
parainfluenza	358 (9.61%)	530 (6.86%)	784 (8.07%)	480 (6.35%)	83 (3.50%)	2,235 (7.19%)
rhinovirus	1,754 (47.06%)	3,112 (40.27%)	3,546 (36.51%)	2,738 (36.25%)	682 (28.78%)	11,832 (38.06%)
Comorbidity						
Asthma	281 (7.54%)	493 (6.38%)	650 (6.69%)	514 (6.80%)	216 (9.11%)	2,154 (6.93%)
Chronic Lung Disease	22 (0.59%)	42 (0.54%)	62 (0.64%)	59 (0.78%)	13 (0.55%)	198 (0.64%)
Chronic Obstructive Pulmonary Disease	4 (0.11%)	12 (0.16%)	13 (0.13%)	16 (0.21%)	0	45 (0.14%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for infants and children under five is shown in Figure 28. Figure 29 shows the same data stacked to represent the combined impact of the viruses.

Figure 28: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for infants and children under five



Figure 29: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for infants and children under five



Test positivity rate over time

We included 4,685,482 lab results with known results of infants and children under age five. Of those tests, 524,535 lab results were positive. The test positivity rate for infants and children under age five is shown in Figure 30.

Figure 30: Weekly test positivity rate since October 2020 for infants and children under five



Older adults (age 65 and over)

Our older adults study population consists of 359,783 hospitalizations of 335,864 unique patients (Table 9).

Table 9: Older adults patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	86,006 (100.00%)	94,818 (100.00%)	75,049 (100.00%)	67,918 (100.00%)	12,073 (100.00%)	335,864 (100.00%)
Age Group						
65 - 74 years	36,591 (42.54%)	36,303 (38.29%)	24,670 (32.87%)	22,338 (32.89%)	4,139 (34.28%)	124,041 (36.93%)
75 - 84 years	31,335 (36.43%)	35,510 (37.45%)	29,122 (38.80%)	26,802 (39.46%)	4,731 (39.19%)	127,500 (37.96%)
85+ years	18,080 (21.02%)	23,005 (24.26%)	21,257 (28.32%)	18,778 (27.65%)	3,203 (26.53%)	84,323 (25.11%)
Sex						
Female	42,030 (48.87%)	47,608 (50.21%)	39,518 (52.66%)	35,591 (52.40%)	6,525 (54.05%)	171,272 (50.99%)
Male	43,695 (50.80%)	46,859 (49.42%)	35,193 (46.89%)	31,902 (46.97%)	5,458 (45.21%)	163,107 (48.56%)
Unknown	281 (0.33%)	351 (0.37%)	338 (0.45%)	425 (0.63%)	90 (0.75%)	1,485 (0.44%)
Race						
White	62,072 (72.17%)	71,217 (75.11%)	56,160 (74.83%)	49,410 (72.75%)	8,915 (73.84%)	247,774 (73.77%)
Black or African American	7,059 (8.21%)	7,362 (7.76%)	5,499 (7.33%)	5,661 (8.34%)	1,104 (9.14%)	26,685 (7.95%)
Asian	1,593 (1.85%)	1,776 (1.87%)	1,970 (2.62%)	1,783 (2.63%)	313 (2.59%)	7,435 (2.21%)
Native Hawaiian or Other Pacific Islander	152 (0.18%)	191 (0.20%)	169 (0.23%)	161 (0.24%)	28 (0.23%)	701 (0.21%)
American Indian or Alaska Native	250 (0.29%)	318 (0.34%)	317 (0.42%)	281 (0.41%)	61 (0.51%)	1,227 (0.37%)
Other Race	3,133 (3.64%)	2,846 (3.00%)	2,942 (3.92%)	2,852 (4.20%)	543 (4.50%)	12,316 (3.67%)
Unknown	11,747 (13.66%)	11,108 (11.72%)	7,992 (10.65%)	7,770 (11.44%)	1,109 (9.19%)	39,726 (11.83%)
Ethnicity						

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Hispanic or Latino	4,606 (5.36%)	4,130 (4.36%)	4,245 (5.66%)	4,742 (6.98%)	1,000 (8.28%)	18,723 (5.57%)
Not Hispanic or Latino	66,836 (77.71%)	77,469 (81.70%)	61,595 (82.07%)	56,208 (82.76%)	10,233 (84.76%)	272,341 (81.09%)
Unknown	14,564 (16.93%)	13,219 (13.94%)	9,209 (12.27%)	6,968 (10.26%)	840 (6.96%)	44,800 (13.34%)
Virus						
COVID	82,729 (96.19%)	85,924 (90.62%)	53,159 (70.83%)	43,477 (64.01%)	5,228 (43.30%)	270,517 (80.54%)
HMPV	31 (0.04%)	1,051 (1.11%)	2,123 (2.83%)	1,807 (2.66%)	192 (1.59%)	5,204 (1.55%)
RSV	548 (0.64%)	1,539 (1.62%)	3,000 (4.00%)	4,740 (6.98%)	1,229 (10.18%)	11,056 (3.29%)
influenza	174 (0.20%)	2,520 (2.66%)	9,175 (12.23%)	10,437 (15.37%)	3,118 (25.83%)	25,424 (7.57%)
parainfluenza	562 (0.65%)	1,022 (1.08%)	2,124 (2.83%)	1,983 (2.92%)	411 (3.40%)	6,102 (1.82%)
rhinovirus	1,962 (2.28%)	2,762 (2.91%)	5,468 (7.29%)	5,474 (8.06%)	1,895 (15.70%)	17,561 (5.23%)
Comorbidity						
Asthma	6,435 (7.48%)	8,153 (8.60%)	7,695 (10.25%)	7,515 (11.06%)	1,568 (12.99%)	31,366 (9.34%)
Chronic Lung Disease	6,256 (7.27%)	7,301 (7.70%)	6,489 (8.65%)	6,238 (9.18%)	1,289 (10.68%)	27,573 (8.21%)
Chronic Obstructive Pulmonary Disease	14,543 (16.91%)	19,640 (20.71%)	16,980 (22.63%)	16,435 (24.20%)	3,245 (26.88%)	70,843 (21.09%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for adults 65 and over is shown in Figure 31. Figure 32 shows the same data stacked to represent the combined impact of the viruses.

Figure 31: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for adults 65 years or older



Figure 32: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for adults 65 years or older



Test positivity rate over time

We included 14,406,870 lab results with known results of adults aged 65 and over. Of those tests, 1,038,633 lab results were positive. The test positivity rate for adults aged 65 and over is shown in Figure 33.

Figure 33: Weekly test positivity rate since October 2020 for adults 65 years or older



Discussion and conclusion

In the week of December 23, 2024, respiratory virus-associated hospitalizations accounted for 9.3% of all hospitalizations, a dramatic increase from 3.0% at the end of

November (+209.2%). The largest increases in hospitalization rates were observed for hospitalization associated with influenza (+790.0%), RSV (+144.9%), and COVID (+141.5%), while hospitalizations associated with human metapneumovirus (HMPV) and parainfluenza showed more moderate increases (+84.7% and +67.0%, respectively). Rhinovirus-associated hospitalizations increased marginally (+16.4%). Influenza test positivity experienced the most substantial increase (+219.2%), followed by RSV (+23.8%) and COVID (+32.9%). Meanwhile, parainfluenza, rhinovirus, and HMPV test positivity declined (-32.6%, -26.1%, and -11.1%, respectively).

In the population aged 0–4 years, respiratory virus-associated hospitalizations increased by 33.7% between the weeks of November 25 and December 23, 2024. RSV-associated hospitalizations saw a substantial rise for the third month in a row (+48.7%), now accounting for 7.5% of all hospitalizations within this age group. Influenza-associated hospitalizations experienced the largest increase (+284.5%), followed by HMPV (+92.2%). COVID-associated hospitalizations showed a modest rise (+8.3%), while parainfluenza-associated hospitalizations remained relatively stable (-2.4%). Rhinovirus-associated hospitalizations declined (-21.8%). By late December, 10.7% of all hospitalizations in this age group were associated with a respiratory virus. Influenza test positivity experienced the largest increase (+228.1%), followed by RSV (+7.8%). In contrast, test positivity rates for parainfluenza (-39.6%), rhinovirus (-29.0%), and HMPV (-17.8%) declined. COVID test positivity also decreased slightly (-4.4%). Despite its decline, rhinovirus remained prominent with a test positivity rate of 29.1% as of late December 2024. These trends highlight the continued burden of RSV, influenza, and other respiratory viruses in this vulnerable age group.

Among older adults (age 65 and over), hospitalizations associated with respiratory viruses increased substantially, rising by 257.8% between the weeks of November 25 and December 23, 2024. Influenza-associated hospitalizations saw the most dramatic rise (+875.8%), followed by RSV- (+287.3%), COVID- (+168.9%), and HMPV-associated hospitalizations (+157.2%). Parainfluenza- and rhinovirus-associated hospitalizations also increased, though to a lesser extent (+63.9% and +22.8%, respectively). By late December, respiratory virus-associated hospitalizations accounted for 11.2% of all hospitalizations in this age group. Influenza test positivity experienced the largest increase (+355.3%), followed by RSV (+116.6%) and HMPV (+72.5%). COVID test positivity also rose (+45.6%). Parainfluenza test positivity remained stable (+1.1%), while rhinovirus test positivity declined slightly (-12.8%). These patterns highlight the evolving landscape of respiratory virus activity among older adults, with rising hospitalizations and test positivity for influenza, RSV, and COVID warranting close attention.

Several limitations of our analysis should be noted. All data are preliminary and may change as additional data are obtained. These findings are consistent with data accessed January 13, 2025. These are raw counts and post-stratification methods have not been conducted. This analysis does not include patients hospitalized with a respiratory virus who were not tested or were tested later in their medical care (when laboratory tests results would have returned a negative result). In addition, cohorts with small counts may be suppressed during the de-identification process leading to the appearance of zero patients for a given time period. Moreover, the unknowns in this report either indicate the value was not included in the individual's electronic health record or that it was excluded from the data to protect an individual's identity as a part of Truveta's commitment to privacy (Truveta, 2024).

We will continue to monitor respiratory virus-associated hospitalization overall and for the at-risk populations.

References

Boyce, T. G., Mellen, B. G., Mitchel, E. F., Wright, P. F., & Griffin, M. R. (2000). Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. The Journal of Pediatrics, 137(6), 865-870. https://doi.org/10.1067/mpd.2000.110531

Centers for Disease Control and Prevention. (2023a, April 10). Past seasons estimated influenza disease burden. Table Print. https://www.cdc.gov/flu/about/burden/past-seasons.html

Centers for Disease Control and Prevention. (2023b, April 4). The National Respiratory and Enteric Virus Surveillance System (NREVSS). Dashboard Print. https://www.cdc.gov/surveillance/nrevss/index.html

Centers for Disease Control and Prevention. (2023c, April 10). Influenza Hospitalization Surveillance Network (FluSurv-NET). Interactive Dashboard Print. https://www.cdc.gov/flu/weekly/influenza-hospitalization-surveillance.htm

Centers for Disease Control and Prevention. (2023d, April 10). RSV-NET Interactive Dashboard Print. https://www.cdc.gov/rsv/research/rsv-net/dashboard.html

Committee on Infectious Diseases and Bronchiolitis Guidelines Committee, Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y. A., Murray, D. L., Orenstein, W. A., Rathore, M. H., Sawyer, M. H., Schutze, G. E., Willoughby, R. E., Zaoutis, T. E., Ralston, S. L., Lieberthal, A. S., Meissner, H. C., Alverson, B. K., Baley, J. E., ... Hernández-Cancio, S. (2014). Updated Guidance for Palivizumab Prophylaxis Among

Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics, 134(2), e620-e638. https://doi.org/10.1542/peds.2014-1666

Christopher A Czaja, Lisa Miller, Nisha Alden, Heidi L Wald, Charisse Nitura Cummings, Melissa A Rolfes, Evan J Anderson, Nancy M Bennett, Laurie M Billing, Shua J Chai, Seth Eckel, Robert Mansmann, Melissa McMahon, Maya L Monroe, Alison Muse, Ilene Risk, William Schaffner, Ann R Thomas, Kimberly Yousey-Hindes, Shikha Garg, Rachel K Herlihy, Age-Related Differences in Hospitalization Rates, Clinical Presentation, and Outcomes Among Older Adults Hospitalized With Influenza—U.S. Influenza Hospitalization Surveillance Network (FluSurv-NET), Open Forum Infectious Diseases, Volume 6, Issue 7, July 2019, ofz225, https://doi.org/10.1093/ofid/ofz225

Lee, N., Lui, G. C. Y., Wong, K. T., Li, T. C. M., Tse, E. C. M., Chan, J. Y. C., Yu, J., Wong, S. S. M., Choi, K. W., Wong, R. Y. K., Ngai, K. L. K., Hui, D. S. C., & Chan, P. K. S. (2013). High Morbidity and Mortality in Adults Hospitalized for Respiratory Syncytial Virus Infections. Clinical Infectious Diseases, 57(8), 1069–1077. https://doi.org/10.1093/cid/cit471

Pastula, S. T., Hackett, J., Coalson, J., Jiang, X., Villafana, T., Ambrose, C., & Fryzek, J. (2017). Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012. Open Forum Infectious Diseases, 4(1), ofw270. https://doi.org/10.1093/ofid/ofw270

Shi, T., McAllister, D. A., O'Brien, K. L., Simoes, E. A. F., Madhi, S. A., Gessner, B. D., Polack, F. P., Balsells, E., Acacio, S., Aguayo, C., Alassani, I., Ali, A., Antonio, M., Awasthi, S., Awori, J. O., Azziz-Baumgartner, E., Baggett, H. C., Baillie, V. L., Balmaseda, A., … Nair, H. (2017). Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. The Lancet, 390(10098), 946–958. https://doi.org/10.1016/S0140-6736(17)30938-8

Smits PD, Gratzl S, Simonov M, Nachimuthu SK, Goodwin Cartwright BM, Wang MD, Baker C, Rodriguez P, Bogiages M, Althouse BM, Stucky NL. Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities. Vaccine. 2023 Apr 6;41(15):2447-2455. https://doi.org/10.1016/j.vaccine.2023.02.038. Epub 2023 Feb 16. PMID: 36803895; PMCID: PMC9933320.

Tokars JI, Olsen SJ, Reed C. Seasonal Incidence of Symptomatic Influenza in the United States. Clin Infect Dis. 2018 May 2;66(10):1511-1518. https://doi.org/10.1093/cid/cix1060. PMID: 29206909; PMCID: PMC5934309.

Truveta. (2024). Truveta's Approach to Patient Privacy.
https://resources.truveta.com/patient-privacy